Physician profile
William E Bloch
NPI 1023013505
$8,164.71
in general payments reported to CMS, 2019-2025
46 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $349 · 2021: $1,093 · 2022: $1,920 · 2023: $1,044 · 2024: $1,310 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,899 · Education: $38.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,899.13 |
| Education | $38.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,282.98 | 2019-2025 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $975.04 | 2022-2023 | Aquabeam Robotic System |
| Sumitomo Pharma America, INC. | $716.28 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $525.03 | 2021-2025 | |
| Teleflex LLC | $517.01 | 2021-2025 | Urolift, Barrigel |
| Endo Pharmaceuticals INC. | $351.86 | 2019-2024 | Xiaflex, Aveed |
| Abbvie INC. | $334.95 | 2020-2025 | Lupron Depot |
| Dendreon Pharmaceuticals LLC | $305.74 | 2022-2024 | Provenge |
| Amgen INC. | $251.39 | 2019-2023 | Xgeva |
| Urogen Pharma, INC. | $234.42 | 2021-2025 | Jelmyto |
| Janssen Biotech, INC. | $217.55 | 2019-2025 | Erleada, Akeega, Balversa |
| Blue Earth Diagnostics | $194.27 | 2020-2024 | |
| Immunitybio, INC. | $182.34 | 2024-2025 | |
| Endo USA, INC. | $168.51 | 2024-2025 | Xiaflex, Aveed |
| Antares Pharma, INC. | $162.91 | 2019-2025 | Xyosted |
Show all 45 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$657.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.